MAIA Biotechnology Secures NIH Grant for THIO-101 Trial

The latest announcement is out from MAIA Biotechnology, Inc. ( (MAIA) ).

On September 24, 2025, MAIA Biotechnology announced it received a $2.3 million grant from the National Institutes of Health to expand its THIO-101 Phase 2 clinical trial. This trial evaluates ateganosine as a third-line treatment for advanced non-small cell lung cancer, with the grant supporting U.S. patient enrollment over three years. The trial aims to address the unmet clinical need in third-line NSCLC treatment, where ateganosine has shown promising survival outcomes compared to standard chemotherapy.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program involves ateganosine, a potential first-in-class cancer telomere targeting agent, aimed at treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.

Average Trading Volume: 440,856

Technical Sentiment Signal: Sell

Current Market Cap: $52.79M

Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.